Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia

doi:10.1158/2159-8290.CD-RW2019-188

AACR Publications

AACR logo

Register
Log in
My Cart

Main menu

Home
About
Articles
For Authors
Alerts
News
- Cancer Discovery News
- Journal Press Releases
COVID-19
Webinars
10th Anniversary
Search More

Search for this keyword

Advanced Search

AACR Publications

User menu

Register
Log in
My Cart

Search

Search for this keyword

Advanced search

Home
About
Articles
For Authors
Alerts
News
- Cancer Discovery News
- Journal Press Releases
COVID-19
Webinars
10th Anniversary
Search More

Search for this keyword

Advanced Search

Research Watch

Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia

DOI: 10.1158/2159-8290.CD-RW2019-188 Published February 2020

Article
Info & Metrics

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: December 2019 to January 2021

	Abstract	Full-text HTML	PDF
Total	1194	383	0

Cited By

Article Information

Volume 10, Issue 2, pp. OF8

DOI

https://doi.org/10.1158/2159-8290.CD-RW2019-188

PubMed

31862836

Published By

American Association for Cancer Research

Print ISSN

2159-8274

Online ISSN

2159-8290

History

Published first December 20, 2019.

Article Versions

Previous version (December 20, 2019 - 06:55).
You are viewing the most recent version of this article.

Author Information

View Full Text

PreviousNext

February 2020
Volume 10, Issue 2

Table of Contents
Table of Contents (PDF)
About the Cover
Editorial Board (PDF)

Search for this keyword

View this article with LENS

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia

Message Subject (Your Name) has forwarded a page to you from Cancer Discovery

Message Body (Your Name) thought you would be interested in this article in Cancer Discovery.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia

Cancer Discov February 1 2020 (10) (2) OF8; DOI: 10.1158/2159-8290.CD-RW2019-188

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia

Cancer Discov February 1 2020 (10) (2) OF8; DOI: 10.1158/2159-8290.CD-RW2019-188

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
- Abstract
- Notes
Info & Metrics

Cited By...

Research Watch

Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Deep Learning Algorithm Aids Breast Cancer Detection by Mammography

Show more Research Watch

Clinical Trials

The LSD1 Inhibitor Iadademstat Is Active in Acute Myeloid Leukemia
Intermittent Inhibition of BRAF plus MEK Is Not Beneficial in Melanoma
Anti–PD-1 plus a VEGFR2 Inhibitor Shows Promise in Cervical Cancer

Show more Clinical Trials

Home
Alerts
Feedback
Privacy Policy

Articles

OnlineFirst
Current Issue
Past Issues

Info For

Authors
Subscribers
Advertisers
Librarians

About Cancer Discovery

About the Journal
Editors
Journal Sections
Permissions
Submit a Manuscript

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Main menu

User menu

Search

Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: December 2019 to January 2021

Cited By

Article Information

Article Versions

Author Information

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Research Watch

Clinical Trials

Articles

Info For

About Cancer Discovery